Report cover image

Middle East Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End-use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Aug 14, 2025
Length 150 Pages
SKU # GV20399981

Description

Market Size & Trends

The Middle East point of care molecular diagnostics market size was valued at USD 273.5 million in 2024 and is projected to reach USD 463.0 million by 2033, growing at a CAGR of 6.13% from 2025 to 2033. The Middle East and Africa (MEA) region encompasses countries with both advanced and emerging healthcare systems, offering a diverse landscape for point-of-care (POC) molecular diagnostics. Well-established healthcare markets, such as Saudi Arabia and the UAE, provide streamlined regulatory pathways, robust logistics, and advanced laboratory networks that support market entry and expansion.

Historically, the region has faced significant challenges with communicable diseases such as malaria and typhoid, and events like the Middle East Respiratory Syndrome (MERS) outbreak in 2015 heightened awareness of the need for rapid molecular diagnostics. The COVID-19 pandemic further accelerated adoption, as the Middle East saw an exponential rise in confirmed cases during early 2020, driving demand for portable and near-patient testing technologies.

Target Disease Prevalence

Governments and private healthcare providers in MEA are strategically investing in infrastructure expansion, from upgrading tertiary hospitals to increasing the number of community-based clinics. These initiatives align with the integration of advanced POC molecular testing platforms capable of delivering fast and accurate results without reliance on centralized laboratories. Economic growth in several Gulf countries, including the UAE, Kuwait, and Qatar, is fueling higher healthcare spending, enabling the adoption of premium diagnostics for infectious diseases, chronic conditions, and sexually transmitted infections (STIs). Moreover, increasing patient awareness, higher purchasing power, and the shift toward preventive and personalized healthcare are expected to sustain market growth in the forecasted period.

In Saudi Arabia, government-led Vision 2030 initiatives emphasize localized manufacturing of molecular diagnostics and expanding public-private partnerships, creating a favorable market for POC platforms in both hospital and community health settings. The UAE is emerging as a regional innovation hub, with AI-enabled diagnostic platforms and ultra-rapid molecular testing solutions developed domestically, such as paper-based devices delivering results in under 10 minutes. Kuwait continues to invest in upgrading laboratory networks, with a growing share of testing shifting toward decentralized formats to improve patient turnaround times. Qatar is channeling resources into early disease detection programs, integrating POC molecular systems into primary care to address chronic and infectious disease burdens. Oman is adopting molecular point-of-care solutions in both urban and rural clinics, driven by national programs targeting respiratory infections, tuberculosis, and other high-prevalence conditions. Collectively, these developments position the Middle East as a rapidly advancing market for point-of-care molecular diagnostics, with strong governmental support and a growing appetite for cutting-edge healthcare technologies.

The UAE is witnessing a rise in the adoption of POC testing due to an increase in government initiatives aimed at the promotion of regular screening activities for cancer and other chronic diseases. For instance, the Ministry of Health and Prevention in the UAE regularly holds breast cancer screening programs, while the Department of Health-Abu Dhabi recommends & encourages frequent screening. Furthermore, the Ministry of Health & Prevention has launched several programs, such as the National Strategy for Fighting Diabetes, for reducing diabetes prevalence in the country.

Middle East Point of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East point-of-care molecular diagnostics market report on the basis of application, technology, test location, end-use, and region:
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
  • HIV POC
  • Clostridium difficile POC
  • HBV POC
  • Pneumonia or Streptococcus associated infections
  • Respiratory syncytial virus (RSV) POC
  • HPV POC
  • Influenza/Flu POC
  • HCV POC
  • MRSA POC
  • TB and drug-resistant TB POC
  • HSV POC
  • Other Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Growing Demand for Rapid and Decentralized Testing
3.4.2. Rising Prevalence of Infectious Diseases
3.4.3. Technological Advancements in Molecular Platforms
3.5. Market Restraint Analysis
3.5.1. High Cost of Molecular POC Devices and Consumables
3.5.2. Regulatory and Quality Assurance Challenges
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Middle East Point of Care Molecular Diagnostics market: Technology Movement Analysis
4.2. PCR-based
4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
4.3. Genetic Sequencing-based
4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
4.4. Hybridization-based
4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
4.5. Microarray-based
4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
5.1. Middle East Point of Care Molecular Diagnostics Market: Application Movement Analysis
5.2. Infectious Diseases
5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
5.2.2. HIV POC
5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
5.2.3. Clostridium difficile POC
5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
5.2.4. HBV POC
5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
5.2.5. Pneumonia or Streptococcus associated infections
5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
5.2.6. Respiratory Syncytial Virus (RSV) POC
5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
5.2.7. HPV POC
5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
5.2.8. Influenza/Flu POC
5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
5.2.9. HCV POC
5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
5.2.10. MRSA POC
5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
5.2.11. TB and drug-resistant TB POC
5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
5.2.12. HSV POC
5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
5.2.13. Other Infectious Diseases
5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
5.3. Oncology
5.3.1. Oncology Market, 2021 - 2033 (USD Million)
5.4. Hematology
5.4.1. Hematology Market, 2021 - 2033 (USD Million)
5.5. Prenatal Testing
5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
5.6. Endocrinology
5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Test Location Business Analysis
6.1. Middle East Point of Care Molecular Diagnostics Market: Test Location Movement Analysis
6.2. OTC
6.2.1. OTC Market, 2021 - 2033 (USD Million)
6.3. POC
6.3.1. POC Market, 2021 - 2033 (USD Million)
Chapter 7. End Use Business Analysis
7.1. Middle East Point of Care Molecular Diagnostics Market: End Use Movement Analysis
7.2. Decentralized Labs
7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
7.3. Hospitals
7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
7.4. Homecare
7.4.1. Home-care Market, 2021 - 2033 (USD Million)
7.5. Assisted Living Healthcare Facilities
7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Middle East Point of Care Molecular Diagnostics Market Share By Region, 2023 & 2033
8.2. MEA
8.2.1. MEA Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.2. Qatar
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. South Africa Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.3. Saudi Arabia
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Saudi Arabia Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.4. UAE
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. UAE Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.5. Oman
8.2.5.1. Key Country Dynamics
8.2.5.2. Target Disease Prevalence
8.2.5.3. Competitive Scenario
8.2.5.4. Regulatory Framework
8.2.5.5. Reimbursement Scenario
8.2.5.6. Oman Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.2.6. Kuwait
8.2.6.1. Key Country Dynamics
8.2.6.2. Target Disease Prevalence
8.2.6.3. Competitive Scenario
8.2.6.4. Regulatory Framework
8.2.6.5. Reimbursement Scenario
8.2.6.6. Kuwait Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Middle East Point of Care Molecular Diagnostics market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Abbott
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Bayer AG
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. F. Hoffmann-La Roche AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Nova Biomedical
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. QIAGEN
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Nipro Diagnostics
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Danaher
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Bio-Rad Laboratories, Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. bioMérieux
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Agilent Technologies, Inc.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.3.11. Abaxis
9.3.3.11.1. Company Overview
9.3.3.11.2. Financial Performance
9.3.3.11.3. Product Benchmarking
9.3.3.11.4. Strategic Initiatives
9.3.3.12. OraSure Technologies
9.3.3.12.1. Company Overview
9.3.3.12.2. Financial Performance
9.3.3.12.3. Product Benchmarking
9.3.3.12.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us